FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133578840> ?p ?o ?g. }

• W3133578840 abstract "Since the start of the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 2 million deaths worldwide. Multiple vaccines have been deployed to date, but the continual evolution of the viral receptor-binding domain (RBD) has recently challenged their efficacy. In particular, SARS-CoV-2 variants originating in the U.K. (B.1.1.7), South Africa (B.1.351) and New York (B.1.526) have reduced neutralization activity from convalescent sera and compromised the efficacy of antibody cocktails that received emergency use authorization. Whereas vaccines can be updated periodically to account for emerging variants, complementary strategies are urgently needed to avert viral escape. One potential alternative is the use of camelid VHHs (also known as nanobodies), which due to their small size can recognize protein crevices that are inaccessible to conventional antibodies. Here, we isolate anti-RBD nanobodies from llamas and “nanomice” we engineered to produce VHHs cloned from alpacas, dromedaries and camels. Through binding assays and cryo-electron microscopy, we identified two sets of highly neutralizing nanobodies. The first group expresses VHHs that circumvent RBD antigenic drift by recognizing a region outside the ACE2-binding site that is conserved in coronaviruses but is not typically targeted by monoclonal antibodies. The second group is almost exclusively focused to the RBD-ACE2 interface and fails to neutralize pseudoviruses carrying the E484K or N501Y substitutions. Notably however, they do neutralize the RBD variants when expressed as homotrimers, rivaling the most potent antibodies produced to date against SARS-CoV-2. These findings demonstrate that multivalent nanobodies overcome SARS-CoV-2 variant mutations through two separate mechanisms: enhanced avidity for the ACE2 binding domain, and recognition of conserved epitopes largely inaccessible to human antibodies. Therefore, while new SARS-CoV-2 mutants will continue to emerge, nanobodies represent promising tools to prevent COVID-19 mortality when vaccines are compromised." @default.
• W3133578840 created "2021-03-15" @default.
• W3133578840 creator A5001960560 @default.
• W3133578840 creator A5003170920 @default.
• W3133578840 creator A5003699560 @default.
• W3133578840 creator A5017948966 @default.
• W3133578840 creator A5024451080 @default.
• W3133578840 creator A5025317946 @default.
• W3133578840 creator A5029045382 @default.
• W3133578840 creator A5035400928 @default.
• W3133578840 creator A5042543645 @default.
• W3133578840 creator A5043677118 @default.
• W3133578840 creator A5049556755 @default.
• W3133578840 creator A5053636210 @default.
• W3133578840 creator A5062721255 @default.
• W3133578840 creator A5063741386 @default.
• W3133578840 creator A5065854870 @default.
• W3133578840 creator A5066892149 @default.
• W3133578840 creator A5069049986 @default.
• W3133578840 creator A5069472918 @default.
• W3133578840 creator A5076693995 @default.
• W3133578840 creator A5080308473 @default.
• W3133578840 creator A5086462012 @default.
• W3133578840 creator A5089331926 @default.
• W3133578840 date "2021-03-04" @default.
• W3133578840 modified "2023-10-14" @default.
• W3133578840 title "Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants" @default.
• W3133578840 cites W1532849119 @default.
• W3133578840 cites W2005485091 @default.
• W3133578840 cites W2019486739 @default.
• W3133578840 cites W2161511521 @default.
• W3133578840 cites W2169610187 @default.
• W3133578840 cites W2783812192 @default.
• W3133578840 cites W2786832567 @default.
• W3133578840 cites W2898721059 @default.
• W3133578840 cites W2979821561 @default.
• W3133578840 cites W2986725225 @default.
• W3133578840 cites W3014067025 @default.
• W3133578840 cites W3017133925 @default.
• W3133578840 cites W3034202401 @default.
• W3133578840 cites W3034425032 @default.
• W3133578840 cites W3036386821 @default.
• W3133578840 cites W3036529319 @default.
• W3133578840 cites W3041222256 @default.
• W3133578840 cites W3044482768 @default.
• W3133578840 cites W3044702419 @default.
• W3133578840 cites W3044914269 @default.
• W3133578840 cites W3081714253 @default.
• W3133578840 cites W3087347658 @default.
• W3133578840 cites W3089112814 @default.
• W3133578840 cites W3091054887 @default.
• W3133578840 cites W3095441755 @default.
• W3133578840 cites W3096751000 @default.
• W3133578840 cites W3104727101 @default.
• W3133578840 cites W3116103971 @default.
• W3133578840 cites W3119147846 @default.
• W3133578840 cites W3121332187 @default.
• W3133578840 cites W3125064706 @default.
• W3133578840 cites W3126729284 @default.
• W3133578840 cites W3127852352 @default.
• W3133578840 cites W3128922954 @default.
• W3133578840 cites W4239659366 @default.
• W3133578840 cites W4246504300 @default.
• W3133578840 doi "https://doi.org/10.1101/2021.03.04.433768" @default.
• W3133578840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7941635" @default.
• W3133578840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33688659" @default.
• W3133578840 hasPublicationYear "2021" @default.
• W3133578840 type Work @default.
• W3133578840 sameAs 3133578840 @default.
• W3133578840 citedByCount "15" @default.
• W3133578840 countsByYear W31335788402021 @default.
• W3133578840 countsByYear W31335788402022 @default.
• W3133578840 countsByYear W31335788402023 @default.
• W3133578840 crossrefType "posted-content" @default.
• W3133578840 hasAuthorship W3133578840A5001960560 @default.
• W3133578840 hasAuthorship W3133578840A5003170920 @default.
• W3133578840 hasAuthorship W3133578840A5003699560 @default.
• W3133578840 hasAuthorship W3133578840A5017948966 @default.
• W3133578840 hasAuthorship W3133578840A5024451080 @default.
• W3133578840 hasAuthorship W3133578840A5025317946 @default.
• W3133578840 hasAuthorship W3133578840A5029045382 @default.
• W3133578840 hasAuthorship W3133578840A5035400928 @default.
• W3133578840 hasAuthorship W3133578840A5042543645 @default.
• W3133578840 hasAuthorship W3133578840A5043677118 @default.
• W3133578840 hasAuthorship W3133578840A5049556755 @default.
• W3133578840 hasAuthorship W3133578840A5053636210 @default.
• W3133578840 hasAuthorship W3133578840A5062721255 @default.
• W3133578840 hasAuthorship W3133578840A5063741386 @default.
• W3133578840 hasAuthorship W3133578840A5065854870 @default.
• W3133578840 hasAuthorship W3133578840A5066892149 @default.
• W3133578840 hasAuthorship W3133578840A5069049986 @default.
• W3133578840 hasAuthorship W3133578840A5069472918 @default.
• W3133578840 hasAuthorship W3133578840A5076693995 @default.
• W3133578840 hasAuthorship W3133578840A5080308473 @default.
• W3133578840 hasAuthorship W3133578840A5086462012 @default.
• W3133578840 hasAuthorship W3133578840A5089331926 @default.
• W3133578840 hasBestOaLocation W31335788401 @default.
• W3133578840 hasConcept C14086860 @default.
• W3133578840 hasConcept C142724271 @default.
• W3133578840 hasConcept C159047783 @default.

• next